Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Elevated platelets, advanced BCLC stage tied to poor survival in sorafenib-treated HCC patients

02 Jul 2019

Hepatocellular carcinoma (HCC) patients receiving sorafenib may have poor survival if they present with pretreatment elevated platelets or have advanced Barcelona Clinic Liver Cancer (BCLC) stage, a recent study has shown.

In total, 1,336 patients (median age, 65 years; interquartile range [IQR], 55–71; 70 percent male) were evaluated, of whom 127 received sorafenib and were included in the study. Median overall survival (OS) in all patients was 8 months (IQR, 2–17).

Multivariate analysis revealed that survival was associated with platelets >/<250,000 mm3 (2 vs 8 months; p=0.01) and BCLC stage (A/B, 13 vs C/D, 6 months; p=0.04). Subanalysis of patients also showed the independent association of BCLC stage C and platelets >/<250,000 mm3 with survival (2 vs 5.5 months; p=0.03)

Survival was longer if patients experienced any side effects from sorafenib use (11 vs 2 months; p=0.009). However, patients who stopped sorafenib treatment because of side effects had shorter survival than those who were able to tolerate them and continue treatment (7.5 vs 13 months; p=0.01).

This retrospective analysis sought to examine the efficacy, safety profile and variables associated with survival in HCC patients treated with sorafenib in South America. Between January 2010 and June 2017, the authors examined HCC patients who received sorafenib from eight medical centres in five South American countries.

OS, which was defined as time from sorafenib initiation to death or last follow-up, was the primary endpoint of the study. Cox proportional hazard regression and log-rank tests were used to assess the risk factors for decreased OS.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.